 Tiziana Life Sciences PLC LON:TILS, NASDAQ:TLSA said it has begun treating a patient with secondary progressive multiple sclerosis using nasally-administered Foralumab, the companys fully-human anti-CD3 monoclonal antibody. The drug will be provided under the Food Drug Administrations individual patient expanded access protocol overseen by researchers at the Brigham and Womens Hospital BWH, Harvard. 